Beyond the first proof-of-principle efficacy of adjuvant pharmacological hPRL pathway targeting on residual lung metastases of human ER+ breast cancer documented here, future studies will determine the broader usefulness of the NSG-Pro mouse in development and preclinical assessment of novel adjuvant therapies for disseminated disease. The gene discussed is ESR1; the disease is breast cancer.